Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib
Ferhat Ferhatoglu1, Senem Karabulut2, Nail Paksoy2, Didem Tastekin21Department of Medical Oncology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey, 2Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey
Objectives: Sunitinib is the preferred second-line treatment option to imatinib escalation in patients with imatinibresistant advanced gastrointestinal stromal tumors. In this study, we aimed to determine the risk factors affecting survival and sunitinib-related toxicities in imatinib-resistance GIST patients. Methods: Clinical characteristics of 40 imatinib-resistant GIST patients who received second-line sunitinib were evaluated. Statistical analysis was performed to determine risk factors associated with survival and sunitinib-related toxicities. Results: The median age was 53 and the male to female ratio was 24/16. The most common of the primary tumor location was small bowel (25; 62.5%). There were 17 (42.5%) patients who developed resistance to imatinib within the first 24 months. Median overall survival (OS) and progression-free survival were 31.6 months and 19.6 months, respectively. Among many risk factors, best response to sunitinib (Hazard ratio [HR]: 2.34) and imatinib resistance (HR: 0.43 were independent prognostics for OS. The only risk factor for sunitinib-related grade 3 or 4 toxicity was advanced age (Odds ratio: 1.90). Conclusion: Long-term use of imatinib and best response to sunitinib are the most important clinical parameters to evaluate the efficacy of sunitinib. Sunitinib-related toxicity is frequently observed and has a high potential for toxicity in elderly patients. Keywords: Adrenal, adrenalectomy, laterality, lung cancer, survival
Cite This Article
Ferhatoglu F, Karabulut S, Paksoy N, Tastekin D. Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib. EJMI. 2022; 6(3): 292-298
Corresponding Author: Ferhat Ferhatoglu